Treatment of the hepatoma and hepatocellular carcinoma cell lines, HepG2 and HuH7, respectively, with the novel PGAM5 inhibitor LFHP-1c inhibited cell growth after 24 h at all concentrations tested (Figure 1A,B). Here, PGAM5 is linked to hepatocellular carcinoma.